Jun 2026 (Q2 FY26) — Jul 27, 2026
Amkor Q2 FY26 — Record Revenue and Strong Profitability Driven by Advanced Packaging and AI Demand
Read the full callAmkor earnings: last reported Mon, 27 Jul 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,685 | +27.5% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 6.0 | +3.6 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 83.4 | +294.5% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
Guidance
46 of 51 judged targets kept · 22 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| EPS | $0.42 to $0.52 | Mar 2026 | Earnings per share was $0.70, a significant increase from the prior year, reflecting the benefits of higher utilization. | Achieved |
| Bridge technology production | bring that into production | Dec 2024 | If I think forward, you mentioned bridge-type technologies, again, that would be more of a 2028 type timeline. | Delayed |
| Operating expenses | approximately $135 million | Dec 2025 | Operating expenses were $139 million for Q1. | Missed |
5 of AMKOR TECHNOLOGY, INC.'s 73 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 70 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: $31.29 on 17 Oct 2025 → $41.89. High $93.55 (22 Jun 2026), low $30.19 (20 Nov 2025).
Overview
Guidance
46 of 51 judged targets kept · 22 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| EPS | $0.42 to $0.52 | Mar 2026 | Earnings per share was $0.70, a significant increase from the prior year, reflecting the benefits of higher utilization. | Achieved |
| Bridge technology production | bring that into production | Dec 2024 | If I think forward, you mentioned bridge-type technologies, again, that would be more of a 2028 type timeline. | Delayed |
| Operating expenses | approximately $135 million | Dec 2025 | Operating expenses were $139 million for Q1. | Missed |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 73 tracked commitments, with each call’s wording and source.
Call summaries
Amkor Q2 FY26 — Record Revenue and Strong Profitability Driven by Advanced Packaging and AI Demand
Read the full callAmkor Technology Q1 FY26 — Record Revenue and Advanced Packaging Momentum
Read the full callEvery analysed call
Financials
Net profit, year on year: +295% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,461 | 1,862 | 1,629 | 1,322 | 1,511 | 1,987 | 1,888 | 1,685 |
| Operating profit | 82 | 149 | 134 | 32 | 92 | 159 | 185 | 100 |
| Operating margin | 5.6% | 8.0% | 8.3% | 2.4% | 6.1% | 8.0% | 9.8% | 6.0% |
| Other income | 0 | -7 | 1 | -6 | -9 | -5 | -4 | -4 |
| Interest | 16 | 16 | 17 | 17 | 17 | 21 | 21 | 18 |
| Profit before tax | 82 | 142 | 136 | 26 | 83 | 154 | 181 | 96 |
| Tax rate | 17.6% | 13.5% | 22.0% | 15.3% | 33.8% | 17.9% | 4.8% | 12.8% |
| Net profit | 67 | 123 | 106 | 21 | 54 | 127 | 172 | 83 |
| EPS ($ per share) | 0.27 | 0.50 | — | 0.09 | 0.22 | 0.51 | — | 0.34 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 113 | 234 | 563 | 1,164 | 1,875 | 2,160 | 2,335 | 2,627 |
| Total liabilities | 2,640 | 2,705 | 2,668 | 3,066 | 3,122 | 2,776 | 2,761 | 3,630 |
| Fixed assets | 2,650 | 2,405 | 2,566 | 2,871 | 3,136 | 3,299 | 3,576 | 3,871 |
| Investments | — | 6 | 134 | 252 | 282 | 475 | 513 | 613 |
| Total assets | 4,495 | 4,696 | 5,022 | 6,039 | 6,822 | 6,771 | 6,944 | 8,136 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 663 | 564 | 770 | 1,121 | 1,099 | 1,270 | 1,089 | 1,096 |
| Cash from investing | -537 | -462 | -639 | -944 | -1,007 | -952 | -800 | -885 |
| Cash from financing | -41 | 108 | -334 | -30 | 56 | -149 | -260 | 99 |
| Net cash flow | 85 | 210 | -196 | 129 | 131 | 158 | 14 | 312 |
| Capital expenditure | -547 | -472 | -553 | -780 | -908 | -749 | -744 | -905 |
| Free cash flow | 116 | 91 | 217 | 342 | 190 | 521 | 345 | 191 |
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +25.6% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
191 filings between Nov 4, 2025 and Oct 13, 2026.
Purchases
None
No insider bought shares.
Sales
$992.17M
42 sales by 12 insiders
50% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 30 gifts.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| 915 Investments, LP | — | $484.90M | Feb 12, 2026 |
| KIM JOHN T | — | $484.90M | Feb 12, 2026 |
| Rutten Guillaume Marie Jean | — | $9.19M | Aug 6, 2026 |
| ROGERS MARK N | — | $3.91M | Aug 17, 2026 |
| Tily Gil C. | — | $2.09M | May 11, 2026 |
| Carolin Roger Anthony | — | $1.52M | May 5, 2026 |
| Engel Kevin | — | $1.51M | Jul 30, 2026 |
| CHURCHILL WINSTON J | — | $1.15M | Jun 12, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 13, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $46.9K |
| Oct 2, 2026 | ALEXANDER DOUGLAS A Director | Sale 10b5-1 plan | 5,000 | $275.0K |
| Oct 2, 2026 | ALEXANDER DOUGLAS A Director | Option exercise 10b5-1 plan | 5,000 | $42.5K |
| Sep 8, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $49.0K |
| Aug 17, 2026 | ROGERS MARK N EVP & General Counsel | Sale 10b5-1 plan | 5,000 | $298.9K |
| Aug 17, 2026 | ROGERS MARK N EVP & General Counsel | Option exercise 10b5-1 plan | 5,000 | $37.0K |
| Aug 11, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $54.5K |
| Aug 7, 2026 | ALEXANDER DOUGLAS A Director | Sale 10b5-1 plan | 5,000 | $279.1K |
| Aug 7, 2026 | ALEXANDER DOUGLAS A Director | Option exercise 10b5-1 plan | 5,000 | $42.5K |
| Aug 6, 2026 | Rutten Guillaume Marie Jean Director | Sale | 25,000 | $1.36M |
| Aug 5, 2026 | Rutten Guillaume Marie Jean Director | Sale | 25,000 | $1.38M |
| Jul 30, 2026 | Engel Kevin President and CEO | Sale | 3,221 | $151.4K |
| Jul 30, 2026 | CHURCHILL WINSTON J Director | Gift | 100 | $0 |
| Jul 20, 2026 | KIM AGNES C Insider | Option exercise | 200,000 | $1.97M |
| Jul 20, 2026 | KIM JAMES J 10% owner | Option exercise | 200,000 | $1.97M |
| Jul 20, 2026 | KIM AGNES C Insider | Option exercise | 250,000 | $2.37M |
| Jul 20, 2026 | KIM JAMES J 10% owner | Option exercise | 250,000 | $2.37M |
| Jul 16, 2026 | ROGERS MARK N EVP & General Counsel | Sale 10b5-1 plan | 5,000 | $325.6K |
| Jul 16, 2026 | ROGERS MARK N EVP & General Counsel | Option exercise 10b5-1 plan | 5,000 | $37.0K |
| Jul 14, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $69.9K |
| Jun 30, 2026 | Engel Kevin President and CEO | Option exercise | 8,692 | $0 |
| Jun 30, 2026 | Faust Megan CFO | Option exercise | 8,692 | $0 |
| Jun 30, 2026 | Engel Kevin President and CEO | Tax withheld | 3,725 | $321.2K |
| Jun 30, 2026 | Rutten Guillaume Marie Jean Director | Option exercise | 8,692 | $0 |
| Jun 30, 2026 | Faust Megan CFO | Tax withheld | 3,725 | $321.2K |
| Jun 16, 2026 | ROGERS MARK N EVP & General Counsel | Sale 10b5-1 plan | 5,000 | $431.0K |
| Jun 16, 2026 | ROGERS MARK N EVP & General Counsel | Option exercise 10b5-1 plan | 5,000 | $37.0K |
| Jun 12, 2026 | CHURCHILL WINSTON J Director | Sale | 5,000 | $391.0K |
| Jun 12, 2026 | CHURCHILL WINSTON J Director | Option exercise | 5,000 | $97.0K |
| Jun 12, 2026 | KIM SUSAN Y Director | Award | 9,893 | $0 |
| Jun 9, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $70.3K |
| May 19, 2026 | Faust Megan CFO | Sale 10b5-1 plan | 1,000 | $64.6K |
| May 18, 2026 | ROGERS MARK N EVP & General Counsel | Sale 10b5-1 plan | 5,000 | $358.1K |
| May 18, 2026 | ROGERS MARK N EVP & General Counsel | Option exercise 10b5-1 plan | 5,000 | $37.0K |
| May 13, 2026 | Tily Gil C. Director | Option exercise | 9,893 | $0 |
| May 13, 2026 | WATSON DAVID N Director | Option exercise | 9,893 | $0 |
| May 13, 2026 | Rutten Guillaume Marie Jean Director | Option exercise | 482 | $0 |
| May 13, 2026 | McCourt MaryFrances Director | Option exercise | 9,893 | $0 |
| May 13, 2026 | CHURCHILL WINSTON J Director | Option exercise | 9,893 | $0 |
| May 11, 2026 | Tily Gil C. Director | Sale | 15,000 | $1.16M |
| May 8, 2026 | Rutten Guillaume Marie Jean Director | Sale | 50,000 | $3.71M |
| May 5, 2026 | ALEXANDER DOUGLAS A Director | Sale | 4,657 | $356.6K |
| May 5, 2026 | Carolin Roger Anthony Director | Sale | 20,000 | $1.52M |
| May 5, 2026 | ALEXANDER DOUGLAS A Director | Option exercise | 4,657 | $44.0K |
| May 5, 2026 | Carolin Roger Anthony Director | Option exercise | 20,000 | $234.2K |
| May 5, 2026 | ALEXANDER DOUGLAS A Director | Option exercise | 343 | $2.9K |
| May 5, 2026 | CHURCHILL WINSTON J Director | Sale | 7,000 | $535.1K |
| May 5, 2026 | ALEXANDER DOUGLAS A Director | Sale | 343 | $26.3K |
| Apr 16, 2026 | ROGERS MARK N EVP & General Counsel | Sale | 5,000 | $297.1K |
| Apr 16, 2026 | ROGERS MARK N EVP & General Counsel | Option exercise | 5,000 | $37.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow AMKOR TECHNOLOGY, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading